There May Be Dragons: Mapping 7 New & Emerging Pharma Development Risks


You have to think about things like technology transfers, shipping and logistics, as well as the increasingly complicated regulatory expectations across countries.

Large pharma companies often have the staff and experience to manage and move drug products and ancillaries within and across borders, but new and emerging companies tend to run lean and be scientifically focused. As a result, you may not have the resources or expertise to coordinate development programs across multiple sites, geographies or vendors.

This eBook is designed to help you map seven key risk areas in drug development and clinical services—and build a plan to overcome them.